Regentis Biomaterials Ltd. RGNT PHARMA
Company Overview
Regentis Biomaterials Ltd., a regenerative medicine company, develops and commercializes tissue repair solutions in the United States. It offers Gelrin, a platform based on hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen for the treatment and regeneration of damaged or diseased tissue; and GelrinC, a cell-free and off-the-shelf hydrogel, which is in Phase II clinical trial for the treatment of cartilage injuries in the knee. The company was incorporated in 2004 and is based in Herzliya, Israel.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.38.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Trailing 12 Months Year-on-year growth — earnings -384.3%.
Growth & Price Performance
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | -384.27% |
Stock Price Performance
| 1 Year: | -72.80% |
| 6 Months: | -39.29% |
| 3 Months: | +59.38% |
| 1 Month: | +7.94% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- RSI (14)47.28 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Generates positive free cash flow.
CONS
- Trading 78.3% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | RGNT Regentis Biomaterials Ltd. PHARMA | 2.04 | -0.09 | $14.33M | 0.00% | - | - | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | - | 1.41M | 1.93M | -932.00K | 8.62M |
| Operating Income | - | -1.41M | -1.93M | 932.00K | -8.62M |
| EBITDA | - | -1.45M | -3.96M | 4.97M | -13.32M |
| Interest Expense | - | 0 | 173.00K | 171.00K | 324.00K |
| Pretax Income | - | -1.45M | -4.13M | 4.80M | -13.65M |
| Tax Provision | - | - | - | - | - |
| Net Income | - | -1.45M | -4.13M | 4.80M | -13.65M |
| Diluted EPS | -1.00 | -0.29 | -0.81 | 0.92 | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 1.72M | 360.00K | 482.00K | 7.62M |
| Current Assets | - | 1.72M | 360.00K | 482.00K | 7.62M |
| Cash & Equivalents | - | 1.24M | 345.00K | 229.00K | 7.38M |
| Inventory | - | - | - | - | - |
| Receivables | - | 26.00K | 8.00K | 73.00K | 230.00K |
| Total Liabilities | - | 43.78M | 46.27M | 41.59M | 2.87M |
| Current Liabilities | - | 2.61M | 3.14M | 6.49M | 2.87M |
| Long Term Debt | 6.08M | 6.47M | 7.41M | - | - |
| Total Debt | - | 6.47M | 7.62M | 4.95M | 1.20M |
| Total Equity | - | -42.06M | -45.91M | -41.10M | 4.74M |
| Shares Outstanding | - | 4.93M | 4.93M | 5.18M | 5.18M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Operating Cash Flow | -1.50M | -1.22M | -641.00K | -1.38M |
| Investing Cash Flow | - | - | - | - |
| Financing Cash Flow | 0 | 325.00K | 525.00K | 8.52M |
| Capital Expenditure | - | - | - | - |
| Free Cash Flow | -1.50M | -1.22M | -641.00K | -1.38M |
| Net Change in Cash | -1.50M | -895.00K | -116.00K | 7.15M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - |
| Net Margin % | - | - | - | - | - |
| ROE % | - | 3.4% | 9.0% | -11.7% | -287.7% |
| ROCE % | - | 157.7% | 69.5% | -15.5% | -181.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Rosalind Advisors, Inc. | 9.99% | 701.68K | $1.27M |
| 2 | Warberg Asset Management LLC | 1.24% | 86.98K | $157.43K |
| 3 | Jane Street Group, LLC | 0.62% | 43.33K | $78.43K |
| 4 | Renaissance Technologies, LLC | 0.19% | 13.35K | $24.16K |
| 5 | UBS Group AG | 0.01% | 434 | $785 |
| 6 | Tower Research Capital LLC (TRC) | - | 11 | $19 |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for RGNT
Why Is Regentis Biomaterials Stock Rising On Wednesday? - Benzinga
<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxPR0J4dDhNbTRyZ2xqTEFFN0M1aklrTnd6UlBicFZ1c0NkN2U4UkNKb3otaGJFeHIwam1JSG5seHNGOElmLUhRYWY4Mk4zdV9tMDNwdU1tR2g2QTBDZHVEeU9GZHBoaTQwa2doWjV2QU5tMHhvVk5JcUFCTW9rRHhCcncycXRhN3JoMnFmZ0…
RGNT - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTFBqbXlPTUllN2duNkdzal9QX3NfeVNkSU9DaWRMaWpwSzJPb0pTTUpQREJjUk9PRExOemFFUHp0YTRHX0M1Nmc?oc=5" target="_blank">RGNT</a> <font color="#6f6f6f">Finviz</font>…
Why Did RGNT Stock Surge More Than 850% Today? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMisAFBVV95cUxOb1BSTVlzUXQ2ZUVlZ1Atamt1Z2VaR2dxd1pfOGJnMmo0RWpLRklBNVZJTTBjYTllc2pSLXd6VE9vS3VXcGY4UWxZcG5mWTh3Q2xHdEFXU2cyU2I0bFJCNUJ4Ymk3NC1BSzF0R1ZSSC1pVVRDX0cwXzZiZ2YtdlpYVTJYVFVfU3lNdWhSa3…
RGNT Stock Erupts As GelrinC European Rollout Plans Ignite Trading - StocksToTrade
<a href="https://news.google.com/rss/articles/CBMihAFBVV95cUxPY0JfTE5wN29Ra3hZUzBsZ0RzTlZGSzI2MjEtRVlTRjhfd0w4UzExcWdiVVBjdXlCZ0paNUl6Ulp0ME5CTi0yYm00Y2t2cE5rS3NSTjlwYzFzN2FwcDRvdlhkY3FFbmdYWnNaYVV5YjBGMjFrSEVCZE5oR0l2TmVZeUxhSEo?oc=5" targ…
These stocks are moving in today's after hours session - ChartMill
<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxPalhrSkN6OWRRM28wVDh0dTdlZzR6RjloQVhzTWU5MEZmNXFBY2lEVVA4ZHRjNWsxRXFxeW1NcmZ3WjdGaS1sY2ZHd3R1dUgxWWVyY1QtaVNIU29pNG4zMmNZbHBfTG13Tmw4Q3BjSzItcnpBdF9TYXlfbF9IN3E1UThGU1RHbms3LXhneW…
Regentis Biomaterials Ltd Actuals & Estimates (AMEX:RGNT) - tradingview.com
<a href="https://news.google.com/rss/articles/CBMigwFBVV95cUxOWFgyY1dIUXZ2VHptZDVaanUzQ0VUejBlUnlzc3FGcUI4VEhsR3JZa0dQcU9OQ3F1LU1WSmtPWHJ4bEJ2SXo1TDNFbnYxMC1RYXpsN0tuSHJmNjNJaG1RaDdsVnVOUzB5dVdSUkdiQXhlWGlGZzIwdUFtcUc0MWlqLXRqNA?oc=5" targe…
RGNT — Frequently Asked Questions
What is the current share price of Regentis Biomaterials Ltd. (RGNT)?
As of 2026-09-19 21:16 PDT, Regentis Biomaterials Ltd. (RGNT) trades at $2.04 on NYSE American. Its 52-week range is $1.28 to $9.40.
What is the market capitalisation of RGNT?
Regentis Biomaterials Ltd. (RGNT) has a market capitalisation of $14.33M on NYSE American.
What is the P/E ratio of RGNT?
RGNT trades at a trailing price-to-earnings (P/E) ratio of -0.09. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 1.98.
Is RGNT a good stock to buy?
This page provides a data-driven analysis of Regentis Biomaterials Ltd. (RGNT), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.